These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9576639)

  • 61. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
    Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
    Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
    Davidsson P; Blennow K; Andreasen N; Eriksson B; Minthon L; Hesse C
    Neurosci Lett; 2001 Mar; 300(3):157-60. PubMed ID: 11226635
    [TBL] [Abstract][Full Text] [Related]  

  • 63. FDA approves new cholinesterase inhibitor for Alzheimer's disease.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1026, 1028. PubMed ID: 10876742
    [No Abstract]   [Full Text] [Related]  

  • 64. Rivastigmine in vascular dementia.
    Vincent S; Lane R
    Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
    Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
    Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rivastigmine in Alzheimer disease: efficacy over two years.
    Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
    Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 70. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B; Haen E
    Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
    Suh DC; Thomas SK; Valiyeva E; Arcona S; Vo L
    Drugs Aging; 2005; 22(8):695-707. PubMed ID: 16060719
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
    Darreh-Shori T; Meurling L; Pettersson T; Hugosson K; Hellström-Lindahl E; Andreasen N; Minthon L; Nordberg A
    J Neural Transm (Vienna); 2006 Nov; 113(11):1791-801. PubMed ID: 16868793
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
    Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
    Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
    Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
    Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
    Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.
    Grothe DR; Piscitelli SC; Dukoff R; Fullerton T; Sunderland T; Molchan SE
    J Clin Psychopharmacol; 1998 Feb; 18(1):78-81. PubMed ID: 9472847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.